Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.

Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE.

BMC Med. 2007 Jul 19;5:20.

2.
3.

Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated.

Jacobson TA, Wertz DA, Hoy T, Kuznik A, Grochulski D, Cziraky M.

Mayo Clin Proc. 2008 Dec;83(12):1316-25. doi: 10.1016/S0025-6196(11)60779-9. Erratum in: Mayo Clin Proc. 2009 Feb;84(2):208.

PMID:
19046550
4.

Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.

Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.

Clin Ther. 2008 Jan;30(1):195-205. doi: 10.1016/j.clinthera.2008.01.003.

PMID:
18343257
5.

An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).

Smith DG, McBurney CR.

Pharmacoeconomics. 2003;21 Suppl 1:13-23.

PMID:
12648031
6.

Statins and prostate cancer diagnosis and grade in a veterans population.

Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM.

J Natl Cancer Inst. 2011 Jun 8;103(11):885-92. doi: 10.1093/jnci/djr108. Epub 2011 Apr 15.

7.

Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.

Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP.

Expert Opin Pharmacother. 2008 Apr;9(5):669-76. doi: 10.1517/14656566.9.5.669.

PMID:
18345946
8.

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.

JAMA. 2005 Nov 16;294(19):2437-45. Erratum in: JAMA. 2005 Dec 28;294(24):3092.

PMID:
16287954
9.

Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.

Zhou Z, Rahme E, Abrahamowicz M, Tu JV, Eisenberg MJ, Humphries K, Austin PC, Pilote L.

CMAJ. 2005 Apr 26;172(9):1187-94.

10.

Statins for the treatment of dementia.

McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007514. doi: 10.1002/14651858.CD007514.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;7:CD007514.

PMID:
20687089
11.

The association between statins and cancer incidence in a veterans population.

Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, Gaziano JM.

J Natl Cancer Inst. 2008 Jan 16;100(2):134-9. doi: 10.1093/jnci/djm286. Epub 2008 Jan 8.

PMID:
18182618
12.

Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.

Swindle JP, Potash J, Kulakodlu M, Kuznik A, Buikema A.

Am J Geriatr Pharmacother. 2011 Dec;9(6):471-82. doi: 10.1016/j.amjopharm.2011.09.004. Epub 2011 Oct 21.

PMID:
22019005
13.

A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in hypertensive patients without prior cardiovascular disease.

Foody JM, Joyce AT, Jeffers BW, Liu LZ, Benner JS.

Am J Ther. 2011 Mar-Apr;18(2):110-6. doi: 10.1097/MJT.0b013e3181cf12d2.

PMID:
20216383
14.

Statins for the treatment of dementia.

McGuinness B, Craig D, Bullock R, Malouf R, Passmore P.

Cochrane Database Syst Rev. 2014 Jul 8;(7):CD007514. doi: 10.1002/14651858.CD007514.pub3. Review.

PMID:
25004278
15.

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-Rubi├│ P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.

PMID:
16780391
16.

Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.

Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, Salvatore T, Corigliano G, Agrusta M, De Simone G, Gaeta I, Oliviero B, Torella R.

Diabetes Obes Metab. 2000 Dec;2(6):355-62.

PMID:
11225965
17.

Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.

Heintjes EM, Penning-van Beest FJ, Plat AW, Meerding WJ, Webb K, Sturkenboom MC, Herings RM.

Pharmacotherapy. 2012 Jul;32(7):631-41. doi: 10.1002/j.1875-9114.2011.01086.x.

PMID:
22760692
18.

Long-term use of statins reduces the risk of hospitalization for dementia.

Corrao G, Ibrahim B, Nicotra F, Zambon A, Merlino L, Pasini TS, Catapano AL, Mancia G.

Atherosclerosis. 2013 Oct;230(2):171-6. doi: 10.1016/j.atherosclerosis.2013.07.009. Epub 2013 Jul 26.

PMID:
24075740
19.

Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.

Cho Y, Choe E, Lee YH, Seo JW, Choi Y, Yun Y, Wang HJ, Ahn CW, Cha BS, Lee HC, Kang ES.

Metabolism. 2015 Apr;64(4):482-8. doi: 10.1016/j.metabol.2014.09.008. Epub 2014 Sep 28.

PMID:
25312577
20.

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H.

Cochrane Database Syst Rev. 2013 Dec 27;(12):CD008623. doi: 10.1002/14651858.CD008623.pub2. Review.

PMID:
24374462

Supplemental Content

Support Center